8-K: Silexion Therapeutics Submits Phase 2/3 Trial Application in Germany

Silexion Therapeutics has successfully submitted a Clinical Trial Application (CTA) to Germany's BfArM for a Phase 2/3 trial of its SIL204 therapy for KRAS-driven pancreatic cancer.

Summary

• Silexion Therapeutics announced the successful submission of a Clinical Trial Application (CTA) to Germany's Federal Institute for Drugs and Medical Devices (BfArM) for its planned Phase 2/3 clinical trial of SIL204.
• SIL204 is a small interfering RNA (siRNA) product candidate targeting KRAS-driven locally advanced pancreatic cancer (LAPC).
• Germany will serve as the Reporting Member State for the EU program, with the scientific assessment of the trial conducted across the European Union.
• This submission follows positive Scientific Advice from BfArM in December 2025 and recent approval from the Israeli Ministry of Health for the same trial.
• The application is supported by completed two-species toxicology studies showing no systemic organ toxicity and extensive preclinical data.
• The Phase 2/3 trial is planned to initiate in the second quarter of 2026 at leading oncology centers in Germany, other EU member states, and Israel.
• The trial will evaluate SIL204 in combination with standard-of-care chemotherapy using a dual-route administration strategy (intratumoral and systemic).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to the successful regulatory submission and alignment with the company's roadmap, indicating progress in a critical clinical trial.

Positives

• Successful submission of a Clinical Trial Application (CTA) to Germany's BfArM, a key regulatory milestone.
• Germany will act as the Reporting Member State for the EU program, facilitating a streamlined European regulatory process.
• Positive Scientific Advice received from BfArM in December 2025 supports the application.
• Recent approval from the Israeli Ministry of Health to initiate the same Phase 2/3 trial in Israel.
• Completed toxicology studies confirm no systemic organ toxicity.
• Extensive preclinical data supports the application.
• Planned initiation of the Phase 2/3 trial in the second quarter of 2026 remains on track.
• The trial will utilize an innovative dual-route administration strategy for SIL204.

Negatives

• Pancreatic cancer remains a highly lethal malignancy with a low five-year survival rate (below 13%).
• More than 80% of pancreatic cancer mortality is driven by metastatic disease, which SIL204 aims to address.
• The company is advancing its lead, second-generation, product candidate, SIL204, indicating potential challenges with first-generation candidates.

Risks

• The outcome of the CTA review in Germany and other jurisdictions is uncertain.
• Silexion's ability to successfully initiate and conduct clinical trials, including the Phase 2/3 trial of SIL204, is subject to risks.
• Regulatory environment and compliance complexities could impact development timelines and outcomes.
• The company may require additional capital to fund its operations and clinical trials.
• There is a risk that Silexion may not be able to maintain its Nasdaq listing.
• Forward-looking statements are subject to risks, uncertainties, and assumptions, and actual results may differ materially.

Future Outlook

The company plans to initiate its Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer in the second quarter of 2026, following the successful submission of its CTA to Germany and approval in Israel. The trial will be conducted across multiple jurisdictions in Europe and Israel.

Management Comments

• "The successful submission of our Phase 2/3 clinical trial application to Germany is a defining milestone that extends SIL204's development into Europe and positions Silexion to advance one of the most innovative RNAi programs in KRAS-driven cancer across multiple major jurisdictions."
• "Germany is widely regarded as one of the most rigorous and respected regulatory environments in the world, and its role as our Reporting Member State under the EU Clinical Trials Regulation provides a strong foundation for our broader European Phase 2/3 program."
• "With the recent Israeli Ministry of Health approval in hand and now our European filing successfully in place, we are executing against every pillar of our 2026 regulatory roadmap as we prepare to initiate the Phase 2/3 trial in the second quarter of this year."

Industry Context

StockSavvy.ai notes that the successful submission of a CTA to Germany's BfArM for a Phase 2/3 trial of SIL204 in KRAS-driven pancreatic cancer represents a significant step for Silexion Therapeutics. This aligns with the broader industry trend of developing targeted therapies for specific genetic mutations like KRAS, which are prevalent in difficult-to-treat cancers. The company's focus on RNAi technology positions it within a competitive but promising area of drug development.

Stakeholder Impact

• Shareholders: Positive impact due to progress in clinical development, potentially increasing the value of the company and its lead candidate.
• Patients: Potential future benefit from a new therapeutic option for KRAS-driven pancreatic cancer.
• Healthcare Providers: Opportunity to participate in a new clinical trial and potentially offer an innovative treatment.

Next Steps

• Await approval of the CTA from Germany's BfArM and other EU member states.
• Initiate the Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer in the second quarter of 2026.
• Conduct the trial at leading oncology centers in Germany, additional EU member states, and Israel.
• Evaluate SIL204 in combination with standard-of-care chemotherapy.

Key Dates

Recommendation

The filing indicates positive progress with a key regulatory submission for a promising drug candidate. However, the trial is still in its early stages (Phase 2/3 initiation), and significant clinical and regulatory hurdles remain. Therefore, a 'hold' recommendation is appropriate, pending further clinical data and regulatory outcomes.

Keywords

Silexion Therapeutics, SIL204, Pancreatic Cancer, KRAS-driven cancer, RNAi therapy, Clinical Trial Application, BfArM, Phase 2/3 trial